Compare CVM & LFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CVM | LFT |
|---|---|---|
| Founded | 1983 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.6M | 35.8M |
| IPO Year | 1996 | 2012 |
| Metric | CVM | LFT |
|---|---|---|
| Price | $1.63 | $4.28 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $12.50 | N/A |
| AVG Volume (30 Days) | ★ 266.9K | 29.8K |
| Earning Date | 11-05-2026 | 11-11-2026 |
| Dividend Yield | N/A | ★ 37.83% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $264,033.00 | N/A |
| Revenue This Year | N/A | $168.78 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 65.45 | N/A |
| 52 Week Low | $0.89 | $4.14 |
| 52 Week High | $9.35 | $69.35 |
| Indicator | CVM | LFT |
|---|---|---|
| Relative Strength Index (RSI) | 43.40 | 43.95 |
| Support Level | $1.01 | N/A |
| Resistance Level | $1.68 | $5.83 |
| Average True Range (ATR) | 0.24 | 0.28 |
| MACD | -0.06 | 0.15 |
| Stochastic Oscillator | 8.48 | 5.51 |
CEL-SCI Corp is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. The company is focused on the development of the following product candidates and technologies: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; 2) LEAPS (Ligand Epitope Antigen Presentation System) technology, for the potential treatment of rheumatoid arthritis.
Lument Finance Trust Inc operates as a real estate investment trust. The company is engaged in investment, financing, and management of a portfolio of commercial real estate debt investments. It invests in transitional floating-rate commercial real estate mortgage loans, mezzanine loans, preferred equity, commercial mortgage-backed securities, fixed-rate loans, construction loans, and other CRE debt instruments.